These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709 [TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France. Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594 [TBL] [Abstract][Full Text] [Related]
10. Genotypic analysis of HCV 1a by sequencing of the NS3 proteasic region in simeprevir therapy candidates. Liberti A; Raddi A; Cuomo N Infez Med; 2016 Dec; 24(4):272-277. PubMed ID: 28011961 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection. Tavares RCF; Feldner ACCA; Pinho JRR; Uehara SNO; Emori CT; Carvalho-Filho RJ; Silva ISS; Santana RAF; de Castro VFD; Castoli GTF; Cristovão CU; Ferraz MLCG Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):754-758. PubMed ID: 28234637 [TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure. Mohamed S; Bourliere M; Benali S; Oules V; Castellani P; Khiri H; Camus C; Penaranda G; Chiche L; Gonzalez D; Sayada C; Olive D; Halfon P J Clin Virol; 2016 May; 78():36-43. PubMed ID: 26971166 [TBL] [Abstract][Full Text] [Related]
13. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C; Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1. Costa VD; Delvaux N; Brandão-Mello CE; Nunes EP; de Sousa PSF; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):700-706. PubMed ID: 30880098 [TBL] [Abstract][Full Text] [Related]
15. Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy. Abdel-Hameed EA; Rouster SD; Ji H; Ulm A; Hetta HF; Anwar N; Sherman KE; Shata MT Viral Immunol; 2016 May; 29(4):252-8. PubMed ID: 26885675 [TBL] [Abstract][Full Text] [Related]
16. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir. Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410 [TBL] [Abstract][Full Text] [Related]
17. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932 [TBL] [Abstract][Full Text] [Related]
18. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Susser S; Welsch C; Wang Y; Zettler M; Domingues FS; Karey U; Hughes E; Ralston R; Tong X; Herrmann E; Zeuzem S; Sarrazin C Hepatology; 2009 Dec; 50(6):1709-18. PubMed ID: 19787809 [TBL] [Abstract][Full Text] [Related]
19. Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba. Andonov A; Kadkhoda K; Osiowy C; Kaita K Can J Gastroenterol; 2013 Jul; 27(7):414-6. PubMed ID: 23862174 [TBL] [Abstract][Full Text] [Related]
20. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience. Ruggiero T; Proietti A; Boglione L; Milia MG; Allice T; Burdino E; Orofino G; Bonora S; Di Perri G; Ghisetti V Arch Virol; 2015 Nov; 160(11):2881-5. PubMed ID: 26249823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]